Biosimilars
Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versio...
Uloženo v:
| Médium: | Online |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
IntechOpen
2022
|
| Témata: | |
| On-line přístup: | ONIX_20220727_9781838819439_222 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1869515851047108608 |
|---|---|
| collection | Directory of Open Access Books |
| description | Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versions of existing biological medicines and their active ingredients, are now available as more affordable options for patients treated with biologics. This book discusses biosimilars with chapters on clinical trials, regulation, pharmacovigilance, and the interchangeability of biosimilars with biologics. It also addresses future trends in the biosimilars market. |
| format | Online |
| id | doab-20.500.12854ir-90326 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | ojs |
| spelling | doab-20.500.12854ir-903262024-04-01T14:14:49Z Biosimilars Feijó Azevedo, Valderilio Moots, Robert Pharmacology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versions of existing biological medicines and their active ingredients, are now available as more affordable options for patients treated with biologics. This book discusses biosimilars with chapters on clinical trials, regulation, pharmacovigilance, and the interchangeability of biosimilars with biologics. It also addresses future trends in the biosimilars market. 2022-07-27T08:19:52Z 2022-07-27T08:19:52Z 2022 book ONIX_20220727_9781838819439_222 9781838819439 9781838819354 9781839681677 https://directory.doabooks.org/handle/20.500.12854/90326 eng image/jpeg n/a https://www.intechopen.com/books/9829 https://mts.intechopen.com/storage/books/9829/authors_book/authors_book.pdf IntechOpen IntechOpen 10.5772/intechopen.87638 10.5772/intechopen.87638 78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6 9781838819439 9781838819354 9781839681677 IntechOpen 106 open access |
| spellingShingle | Pharmacology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology Biosimilars |
| title | Biosimilars |
| title_full | Biosimilars |
| title_fullStr | Biosimilars |
| title_full_unstemmed | Biosimilars |
| title_short | Biosimilars |
| title_sort | biosimilars |
| topic | Pharmacology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology |
| topic_facet | Pharmacology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology |
| url | ONIX_20220727_9781838819439_222 |